目的 探讨金水宝胶囊联合复方α-酮酸片治疗慢性肾功能衰竭的临床疗效。方法 选取2012年3月-2016年3月在宝鸡市第二人民医院接受治疗的慢性肾功能衰竭患者196例，随机分为对照组（98例）和治疗组（98例）。所有患者均给予常规治疗。对照组口服复方α-酮酸片，4片/次，3次/d。治疗组在对照组的基础上口服金水宝胶囊，3粒/次，3次/d。两组患者均连续治疗2个月。比较两组临床疗效，内生肌酐清除率（Ccr）、血肌酐（Scr）、血清尿素氮（BUN）、转化生长因子-β1（TGF-β1）和Ⅳ型胶原蛋白（IV-C）。结果 治疗后，对照组和治疗组总有效率分别为83.67%和94.90%，两组比较差异有统计学意义（P<0.05）。治疗后，两组Scr、BUN水平均较同组治疗前显著降低，Ccr水平则升高，同组治疗前后差异具有统计学意义（P<0.05）；且治疗后，治疗组这些观察指标显著优于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组TGF-β1和IV-C水平均低于同组治疗前，同组治疗前后差异具有统计学意义（P<0.05）；且治疗后，治疗组TGF-β1、IV-C水平显著低于对照组，两组比较差异具有统计学意义（P<0.05）。结论 金水宝胶囊联合复方α-酮酸片治疗慢性肾功能衰竭具有显著的疗效，可明显改善患者肾功能，降低尿TGF-β1和IV-C水平，具有一定的临床推广应用价值。

Objective To observe the clinical effect of Jinshuibao Capsules combined with Compound α-Ketoacid Tablets in treatment of chronic renal failure. Methods Patients (196 cases) with chronic renal failure in Baoji No. 2 People's Hospital from March 2012 to March 2016 were divided into control (98 cases) and treatment (98 cases) groups. All patients were given conventional treatment. Patients in the control group were po administered with Compound α-Ketoacid Tablets, 4 tablets/time, 3 times daily. Patients in the treatment group were po administered with Jinshuibao Capsules on the basis of control group, 3 grains/time, 3 times daily. The patients in two groups were treated for 2 months. After treatment, the efficacy was evaluated, and Ccr, Scr, BUN, TGF-β1, and IV-C levels in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 83.67% and 94.90%, respectively, and there were differences between two groups (P<0.05). After treatment, Scr and BUN levels in two groups were significantly decreased, and Ccr level was increased, and the difference was statistically significant in the same group (P<0.05). After treatment, the observational indexes in the treatment group were significantly better than those in the control group with significant difference between two groups (P<0.05). After treatment, TGF-β1 and IV-C levels in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). After treatment, TGF-β1 and IV-C levels in the treatment group were significantly lower than those in the control group with significant difference between two groups (P<0.05). Conclusion Jinshuibao Capsules combined with Compound α-Ketoacid Tablets has a clinical curative effect in treatment of chronic renal failure, can significantly improve renal function and reduce urine TGF-β1 and IV-C levels, which has a certain clinical application value.